Coronary vs. Peripheral Applications

The drug eluting balloons market is broadly segmented into two primary applications: coronary and peripheral. While peripheral DEBs currently hold a larger market share, the coronary segment is projected to experience the fastest growth in the coming years. This dichotomy reflects the different clinical needs and regulatory landscapes for treating blockages in these two distinct vascular territories. The market dynamics between these applications are detailed in the Drug Eluting Balloons Market report.

Peripheral DEBs are used to treat blockages in arteries outside the heart, such as in the legs and arms. They have proven particularly effective in the femoropopliteal and below-the-knee (BTK) arteries, which are subject to a lot of movement and external compression. In these areas, the use of a stent can lead to fractures or fatigue, making DEBs a preferred option. The large patient population with peripheral artery disease (PAD), especially in an aging demographic, ensures a sustained demand for these devices. On the other hand, the coronary segment, which deals with arteries supplying the heart, is seeing rapid growth due to expanding clinical evidence and recent regulatory approvals. DEBs are now widely used for in-stent restenosis and are gaining traction for treating de-novo lesions in small coronary vessels. The potential of coronary DEBs to offer a stent-free solution for these challenging cases is driving a surge in their adoption.